EP1689346A4 - Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants - Google Patents
Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondantsInfo
- Publication number
- EP1689346A4 EP1689346A4 EP04811773A EP04811773A EP1689346A4 EP 1689346 A4 EP1689346 A4 EP 1689346A4 EP 04811773 A EP04811773 A EP 04811773A EP 04811773 A EP04811773 A EP 04811773A EP 1689346 A4 EP1689346 A4 EP 1689346A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- monoclonal antibodies
- agonistic monoclonal
- epha2 agonistic
- epha2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52417703P | 2003-11-20 | 2003-11-20 | |
PCT/US2004/039112 WO2005051307A2 (fr) | 2003-11-20 | 2004-11-19 | Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1689346A2 EP1689346A2 (fr) | 2006-08-16 |
EP1689346A4 true EP1689346A4 (fr) | 2007-11-21 |
Family
ID=34632874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04811773A Withdrawn EP1689346A4 (fr) | 2003-11-20 | 2004-11-19 | Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1689346A4 (fr) |
JP (1) | JP4860477B2 (fr) |
KR (1) | KR20060135671A (fr) |
CN (1) | CN1905899B (fr) |
AU (1) | AU2004293034B2 (fr) |
CA (1) | CA2546763A1 (fr) |
WO (1) | WO2005051307A2 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887674B1 (en) | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
US6864227B1 (en) | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
CA2485548A1 (fr) * | 2002-05-10 | 2004-02-19 | Purdue Research Foundation | Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci |
EP1505999A4 (fr) | 2002-05-23 | 2009-07-08 | Purdue Research Foundation | Tyrosine phosphatase de faible poids moleculaire (lmw-ptp) servant de cible a usage diagnostique et therapeutique |
JP2006521111A (ja) | 2003-03-12 | 2006-09-21 | バスジーン セラピューティクス, インコーポレイテッド | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
US7381410B2 (en) | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
ATE492564T1 (de) | 2004-03-12 | 2011-01-15 | Vasgene Therapeutics Inc | Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum |
WO2005090406A2 (fr) | 2004-03-12 | 2005-09-29 | Vasgene Therapeutics, Inc. | Compositions polypeptidiques pour inhiber l'angiogenese et la croissance tumorale |
WO2006023420A2 (fr) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Antagonistes de l'integrine possedant une action cytotoxique a mediation cellulaire dependante de l'anticorps amelioree |
WO2006034455A2 (fr) | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Composes de polypeptides pour l'inhibition de l'angiogenese et de croissance tumorale |
US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
WO2007075706A2 (fr) * | 2005-12-21 | 2007-07-05 | Medimmune, Inc. | Anticorps agonistes d'epha2 a affinites optimisees et methodes d'utilisation de ces anticorps |
AU2008265928A1 (en) * | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Synergistic treatment of cells that express EphA2 and ErbB2 |
CN102083861B (zh) | 2007-08-13 | 2016-04-13 | 瓦斯基因治疗公司 | 使用结合EphB4的人源化抗体的癌症治疗 |
PT2199390T (pt) * | 2007-08-30 | 2017-03-15 | Daiichi Sankyo Co Ltd | Anticorpo anti-epha2 |
KR20130056855A (ko) | 2010-03-01 | 2013-05-30 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 치료진단용 생물학적 지표들 |
AU2011237669B2 (en) | 2010-04-06 | 2016-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for disease |
KR20130048242A (ko) * | 2010-07-22 | 2013-05-09 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 항-종양 항원 항체 및 이용 방법 |
US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
WO2016171242A1 (fr) * | 2015-04-24 | 2016-10-27 | 第一三共株式会社 | Détection d'epha2 |
CN115025217B (zh) * | 2022-05-13 | 2023-05-05 | 广东齐美医药生物科技集团有限公司 | 干细胞裂解物联合活性多糖以及酪氨酸酶抑制剂在制备药物或化妆品中的用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001012172A1 (fr) * | 1999-08-17 | 2001-02-22 | Purdue Research Foundation | Traitement de maladies metastatiques |
WO2003094859A2 (fr) * | 2002-05-10 | 2003-11-20 | Medimmune, Inc. | Anticorps monoclonaux contre epha2 et leurs méthodes d'utilisation |
WO2004014292A2 (fr) * | 2002-05-10 | 2004-02-19 | Purdue Research Foundation | Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci |
WO2005056766A2 (fr) * | 2003-12-04 | 2005-06-23 | Medimmune, Inc. | Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
-
2004
- 2004-11-19 KR KR1020067012152A patent/KR20060135671A/ko not_active Application Discontinuation
- 2004-11-19 CA CA002546763A patent/CA2546763A1/fr not_active Abandoned
- 2004-11-19 CN CN2004800407205A patent/CN1905899B/zh not_active Expired - Fee Related
- 2004-11-19 JP JP2006541599A patent/JP4860477B2/ja not_active Expired - Fee Related
- 2004-11-19 EP EP04811773A patent/EP1689346A4/fr not_active Withdrawn
- 2004-11-19 WO PCT/US2004/039112 patent/WO2005051307A2/fr active Application Filing
- 2004-11-19 AU AU2004293034A patent/AU2004293034B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001012172A1 (fr) * | 1999-08-17 | 2001-02-22 | Purdue Research Foundation | Traitement de maladies metastatiques |
WO2003094859A2 (fr) * | 2002-05-10 | 2003-11-20 | Medimmune, Inc. | Anticorps monoclonaux contre epha2 et leurs méthodes d'utilisation |
WO2004014292A2 (fr) * | 2002-05-10 | 2004-02-19 | Purdue Research Foundation | Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci |
US20040091486A1 (en) * | 2002-05-10 | 2004-05-13 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
WO2005056766A2 (fr) * | 2003-12-04 | 2005-06-23 | Medimmune, Inc. | Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4 |
Non-Patent Citations (4)
Title |
---|
HU MIN ET AL: "Antibody targeting of the EphA2 receptor tyrosine kinase on breast cancer cells.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07-01), & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, pages 1234, XP008079516, ISSN: 0197-016X * |
HU MIN ET AL: "EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells.", MOLECULAR CANCER RESEARCH : MCR OCT 2004, vol. 2, no. 10, October 2004 (2004-10-01), pages 533 - 540, XP002435680, ISSN: 1541-7786 * |
LANDEN CHARLES N JR ET AL: "Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer", JNCI CANCER SPECTRUM, OXFORD UNIVERSITY PRESS, OXFORD, GB, vol. 98, no. 21, 1 November 2006 (2006-11-01), pages 1558 - 1570, XP002421774, ISSN: 1475-4029 * |
MILLER KATHY D ET AL: "EA5, novel EphA2-targeted monoclonal antibody, inhibits growth and metastasis in human breast cancer xenografts.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 46, no. Suppl. S, April 2005 (2005-04-01), & 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ANAHEIM, CA, USA; APRIL 16 -20, 2005, pages 132, XP002435681, ISSN: 0197-016X * |
Also Published As
Publication number | Publication date |
---|---|
CA2546763A1 (fr) | 2005-06-09 |
WO2005051307A3 (fr) | 2006-09-08 |
CN1905899B (zh) | 2011-09-28 |
KR20060135671A (ko) | 2006-12-29 |
AU2004293034B2 (en) | 2012-02-02 |
AU2004293034A1 (en) | 2005-06-09 |
WO2005051307A2 (fr) | 2005-06-09 |
JP4860477B2 (ja) | 2012-01-25 |
EP1689346A2 (fr) | 2006-08-16 |
CN1905899A (zh) | 2007-01-31 |
JP2008500021A (ja) | 2008-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1689346A4 (fr) | Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants | |
HK1219487A1 (zh) | 特異抗體及使用它們的方法 | |
SG10201606980VA (en) | Anti-cd3 antibodies and methods of use thereof | |
IL179102A (en) | Human-specific fcγriib antibodies and methods for their use | |
HK1208472A1 (en) | Antibodies that bind cell-associated ca 125/o722p and methods of use thereof ca125/o772p | |
IL178593A (en) | Specific antibodies of fcγriib and methods for their use | |
IL186659A0 (en) | Il-31 monoclonal antibodies and methods of use | |
EP1614693A4 (fr) | Purification d'un anticorps monoclonal humain et d'un anticorps polyclonal humain | |
IL172689A0 (en) | Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE | |
IL175935A0 (en) | Solid forms of anti-egfr antibodies | |
EP1833849A4 (fr) | Anticorps specifiques de fc gamma riib et leurs procedes d'utilisation | |
IL190502A0 (en) | Anti-addl monoclonal antibody and use thereof | |
EP1717250A4 (fr) | Anticorps monoclonal et utilisation de celui-ci | |
EP1633785A4 (fr) | Anticorps monoclonaux humains diriges contre l'antigene protecteur de bacillus anthracis | |
SI1587542T1 (sl) | Uporaba anti-cd100 protiteles | |
IL205511A0 (en) | Methods and compositions for the production of monoclonal antibodies | |
EP1812065A4 (fr) | Anticorps d'affinité élevée contre la hmgb1 et procédés d'utilisation | |
IL174016A (en) | Monoclonal antibodies to m-csf and their uses | |
HK1098825A1 (en) | Human monoclonal antibodies against cd20 | |
IL149701A0 (en) | Use of anti-ctla-4 antibodies | |
EP1572077A4 (fr) | Utilisations d'anticorps 8h9 monoclonaux | |
AU2003265522A1 (en) | FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
IL182943A0 (en) | Ovr110 antibody compositions and methods of use | |
AU2003220079A8 (en) | Uses of monoclonal antibody 8h9 | |
EP1968998A4 (fr) | Anticorps agonistes d'epha2 à affinités optimisées et méthodes d'utilisation de ces anticorps |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060620 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK YU |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07H 21/04 20060101ALI20061031BHEP Ipc: C07K 16/28 20060101ALI20061031BHEP Ipc: C12P 21/08 20060101ALI20061031BHEP Ipc: A61K 39/395 20060101AFI20061031BHEP |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/20 20060101ALI20071004BHEP Ipc: C12N 15/63 20060101ALI20071004BHEP Ipc: C12N 15/13 20060101ALI20071004BHEP Ipc: A61P 35/00 20060101ALI20071004BHEP Ipc: C07H 21/04 20060101ALI20071004BHEP Ipc: C07K 16/28 20060101ALI20071004BHEP Ipc: C12P 21/08 20060101ALI20071004BHEP Ipc: A61K 39/395 20060101AFI20061031BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20071019 |
|
17Q | First examination report despatched |
Effective date: 20080619 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20081230 |